Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284139 | 1.00 | DRD4 (0.47) | DRD4CYP2A13SLC6A2RAB9ANPC1 | |
| SCHEMBL14203061 | 1.00 | DRD4 (0.47) | DRD4CYP2A13SLC6A2RAB9ANPC1 | |
| SCHEMBL14580282 | 0.93 | SLC6A2 (0.46) | DRD4CYP2A13SLC6A2CNR2CYP1A2 | |
| SCHEMBL14203075 | 0.93 | SLC6A2 (0.46) | DRD4CYP2A13SLC6A2CNR2CYP1A2 | |
| SCHEMBL5044506 | 0.93 | SLC6A2 (0.46) | DRD4CYP2A13SLC6A2CNR2CYP1A2 | |
| SCHEMBL8284121 | 0.85 | SLC6A2 (0.45) | DRD4CYP2A13SLC6A2CYP1A2CYP3A4 | |
| SCHEMBL5437818 | 0.85 | SLC6A2 (0.45) | DRD4CYP2A13SLC6A2CYP1A2CYP3A4 | |
| SCHEMBL14203040 | 0.85 | SLC6A2 (0.45) | DRD4CYP2A13SLC6A2CYP1A2CYP3A4 | |
| SCHEMBL5042305 | 0.84 | SLC6A2 (0.59) | DRD4CYP2A13SLC6A2CNR2CYP1A2 | |
| SCHEMBL14203009 | 0.84 | SLC6A2 (0.59) | DRD4CYP2A13SLC6A2CNR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354920-B2 | Aryl and heteroaryl morpholine derivatives | ELI LILLY AND COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| CN-1889940-A | Treatment of personality changes due to hot flashes, impulse control disorders and systemic medical conditions | LILLY CO ELI (US) | 2007-01-03 | — | — | CN | disclosed |
| EP-1729754-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1660185-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660065-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660064-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060003998-A1 | Aryl and heteroaryl morpholine derivatives | ELI LILLY AND COMPANY (IN) | 2006-01-05 | — | — | US | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1534694-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021095-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004018441-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003998-A1 | Aryl and heteroaryl morpholine derivatives | ADRA2C, HTR2C, ADRB1 | DRD4 36/4885CYP2A13 427/4885SLC6A2 19/4885 |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | DRD4 6/4885CYP2A13 830/4885SLC6A2 1/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | DRD4 11/4885CYP2A13 1705/4885SLC6A2 1/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | DRD4 52/4885CYP2A13 1515/4885SLC6A2 1/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | DRD4 32/4885CYP2A13 719/4885SLC6A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.